Aspira Pathlab Diagnostics Ltd vs Metropolis Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Aspira Pathlab & Diagnostics Ltd is ₹ 143.34 as of 29 Sep 10:20 . The P/E Ratio of Aspira Pathlab & Diagnostics Ltd changed from 43.3 on March 2025 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Metropolis Healthcare Ltd changed from 69.2 on March 2024 to 47.3 on March 2026 . This represents a CAGR of -6.14% over 6 years The Market Cap of Aspira Pathlab & Diagnostics Ltd changed from ₹ 31.91 crore on March 2024 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Metropolis Healthcare Ltd changed from ₹ 8843 crore on March 2024 to ₹ 8992 crore on March 2026 . This represents a CAGR of 0.28% over 6 years The revenue of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Metropolis Healthcare Ltd for the Jun '26 is ₹ 455.32 crore as compare to the Mar '26 revenue of ₹ 432.95 crore. This represent the growth of 5.17% The ebitda of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Metropolis Healthcare Ltd for the Jun '26 is ₹ 116.3 crore as compare to the Mar '26 ebitda of ₹ 116.29 crore. This represent the growth of 0.01% The net profit of Aspira Pathlab & Diagnostics Ltd changed from ₹ 0.05 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Metropolis Healthcare Ltd changed from ₹ 38.11 crore to ₹ 56.88 crore over 9 quarters. This represents a CAGR of 19.48% The Dividend Payout of Aspira Pathlab & Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Metropolis Healthcare Ltd changed from 20.69 % on March 2021 to 65.83 % on March 2026 . This represents a CAGR of 21.28% over 6 years .

About Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973.
ASDL is a leading pathology specialist, with Pan-India presence.
It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses.
The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services. Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers.
Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai. ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results.

About Metropolis Healthcare Ltd

Dr. Sushil Kanubhai Shah, one of the Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners.
The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards.
In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah.
Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis.
On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr.

FAQs for the comparison of Aspira Pathlab & Diagnostics Ltd and Metropolis Healthcare Ltd

Which company has a larger market capitalization, Aspira Pathlab & Diagnostics Ltd or Metropolis Healthcare Ltd?

Market cap of Aspira Pathlab & Diagnostics Ltd is 129 Cr while Market cap of Metropolis Healthcare Ltd is 10,849 Cr

What are the key factors driving the stock performance of Aspira Pathlab & Diagnostics Ltd and Metropolis Healthcare Ltd?

The stock performance of Aspira Pathlab & Diagnostics Ltd and Metropolis Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aspira Pathlab & Diagnostics Ltd and Metropolis Healthcare Ltd?

As of October 25, 2026, the Aspira Pathlab & Diagnostics Ltd stock price is INR ₹126.05. On the other hand, Metropolis Healthcare Ltd stock price is INR ₹522.95.

How do dividend payouts of Aspira Pathlab & Diagnostics Ltd and Metropolis Healthcare Ltd compare?

To compare the dividend payouts of Aspira Pathlab & Diagnostics Ltd and Metropolis Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.